Myelofibrosis (MF) is a rare and life-threatening myeloproliferative disorder characterized by progressive scarring of the bone marrow and a number of severely debilitating symptoms. The objective of this analysis was to estimate cost-effectiveness of ruxolitinib (RUX) in a treatment of MF patients compared with best available therapy (BAT) in Finland.